Chat with us
Research Assistance
Online
  • Please enter your first name.

Canada Nucleic Acid Therapeutics Cdmo Market Size & Outlook

The nucleic acid therapeutics cdmo market in Canada is expected to reach a projected revenue of US$ 2,366.3 million by 2033. A compound annual growth rate of 15.3% is expected of Canada nucleic acid therapeutics cdmo market from 2026 to 2033.

  • HC Outsourcing
    • Clinical & Non-Clinical Outsourcing Services
      • Nucleic Acid Therapeutics CDMO Market Outlook
Revenue, 2025 (US$M)
$760.7
Estimate, 2026 (US$M)
$872.2
Forecast, 2033 (US$M)
$2,366.3
CAGR, 2026 - 2033
15.3%
Canada Nucleic Acid Therapeutics Cdmo Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Ask Prism AI anything about the nucleic acid therapeutics cdmo market

Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.

Every answer starts with GVR research, and every figure is cited.Explore Prism AI

Canada nucleic acid therapeutics cdmo market highlights

  • The Canada nucleic acid therapeutics cdmo market generated a revenue of USD 760.7 million in 2025 and is expected to reach USD 2,366.3 million by 2033.
  • The Canada market is expected to grow at a CAGR of 15.3% from 2026 to 2033.
  • In terms of segment, rna-based therapies was the largest revenue generating type in 2025.
  • RNA-based Therapies is the most lucrative type segment registering the fastest growth during the forecast period.


Nucleic acid therapeutics cdmo market data book summary

Market revenue in 2025USD 760.7 million
Market revenue in 2033USD 2,366.3 million
Growth rate15.3% (CAGR from 2026 to 2033)
Largest segmentRna-based therapies
Fastest growing segmentRNA-based Therapies
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationRNA-based Therapies, Gene Therapy
Key market players worldwideCatalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp


Other key industry trends

  • In terms of revenue, Canada accounted for 4.4% of the global nucleic acid therapeutics cdmo market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In North America, U.S. nucleic acid therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2033.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 2,366.3 million by 2033.

Canada held a market share of 11.2% in North America in 2023. The country is seeking to support healthcare innovation by establishing a pathway for advanced therapeutic products. 

In the country, the well-established biotechnology sector in Canada is likely to leverage the pipeline of promising treatments in this country.

Moreover, in the country, several potentially life-saving cell & gene therapies are in various stages of development and clinical trials. The therapies are designed to combat a range of diseases, including cancer, diabetes, liver disease, rheumatoid arthritis, Alzheimer’s, and many rare conditions.

No credit card required*

Publish Date: Jun 10, 2026

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study
Turnaround
5–10 working days

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Nucleic Acid Therapeutics CDMO Market Companies

NameProfile# EmployeesHQWebsite
Lonza Group LtdView profile 18,000Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002www.lonza.com
FUJIFILM Holdings CorpView profile 83,7847-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052www.fujifilmholdings.com
Thermo Fisher Scientific IncView profile 122,000168 Third Avenue, Waltham, MA, United States, 02451www.thermofisher.com
Danaher CorpView profile 63,0002200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701www.danaher.com
Eurofins Scientific SEView profile 61,79823 Val Fleuri, Luxembourg, Luxembourg, L-1526www.eurofins.com
Charles River Laboratories International IncView profile 21,400251 Ballardvale Street, Wilmington, MA, United States, 01887www.criver.com
Catalent IncView profile 17,21914 Schoolhouse Road, Somerset, NJ, United States, 08873www.catalent.com
PerkinElmerView profile 10001+Waltham, Massachusetts, United States, North Americawww.perkinelmer.com
Oxford Biomedical ResearchView profile 11-50Rochester Hills, Michigan, United States, North Americawww.oxfordbiomed.com/

Canada Nucleic Acid Therapeutics CDMO Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nucleic Acid Therapeutics CDMO Market Outlook will help companies and investors design strategic landscapes.


Rna-Based Therapies was the largest segment with a revenue share of 75.1% in 2025.

Horizon Databook has segmented the Canada nucleic acid therapeutics cdmo market based on rna-based therapies, gene therapy covering the revenue growth of each sub-segment from 2021 to 2033.




Canada held a market share of 11.2% in North America in 2023. The country is seeking to support healthcare innovation by establishing a pathway for advanced therapeutic products. 

In the country, the well-established biotechnology sector in Canada is likely to leverage the pipeline of promising treatments in this country.

Moreover, in the country, several potentially life-saving cell & gene therapies are in various stages of development and clinical trials. The therapies are designed to combat a range of diseases, including cancer, diabetes, liver disease, rheumatoid arthritis, Alzheimer’s, and many rare conditions.

  • Canada Nucleic Acid Therapeutics Cdmo Market Type Outlook (Revenue, USD Million , 2021-2033)
    • Gene Therapy
    • RNA-based Therapies
  • Canada Nucleic Acid Therapeutics Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
    • Process Development and Optimization
    • Manufacturing Services
    • Analytical and Quality Control Services
    • Others
  • Canada Nucleic Acid Therapeutics Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
    • Pharmaceutical Companies
    • Government & Academic Research Institutes
    • Biotech Companies
  • Canada Nucleic Acid Therapeutics Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Rare Diseases
    • Genetic Disorders
    • Infectious Diseases
    • Others

Reasons to subscribe to Nucleic Acid Therapeutics CDMO Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Nucleic Acid Therapeutics CDMO Market Outlook databook

  • Our clientele includes a mix of Nucleic Acid Therapeutics CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada Nucleic Acid Therapeutics CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Nucleic Acid Therapeutics CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Canada Nucleic Acid Therapeutics Cdmo Market, 2021-2033 (US$M)

No Access Stack Chart

Canada nucleic acid therapeutics cdmo market statistics, by type, 2021-2033 (US$M)

No Access Pie Chart

Canada nucleic acid therapeutics cdmo market statistics, by type, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more